Form 4: NovoCure Director Sells Shares to Cover Tax Obligations Following RSU Vesting

NovoCure Ltd. Director Timothy J. Scannell sold 999 ordinary shares at a weighted average price of $17.3165 to satisfy tax withholding obligations related to vested Restricted Stock Units.

Summary

• Timothy J. Scannell, a Director of NovoCure Ltd. (NVCR), reported a transaction on June 3, 2025.
• He sold 999 ordinary shares of NovoCure.
• The sale was executed at a weighted average price of $17.3165 per share, with prices ranging from $17.1025 to $17.50.
• This transaction was a "sell to cover" to meet tax withholding obligations arising from the vesting of Restricted Stock Units, and it does not represent a discretionary trade by the reporting person.
• Following this transaction, Mr. Scannell beneficially owns 6,018 ordinary shares directly.
• The filing also corrects a prior mathematical error in the reported total shares beneficially owned.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a mandatory 'sell to cover' for tax purposes, not indicative of discretionary investment decisions or a change in management's outlook on the company's prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale of 999 ordinary shares by Director Timothy J. Scannell was mandated by the issuer's award agreement to cover tax withholding obligations related to the vesting of Restricted Stock Units and does not represent a discretionary trade by the reporting person.

Industry Context

This Form 4 filing details a routine insider transaction for NovoCure Ltd., which is common for publicly traded companies where executives and directors receive equity compensation that often necessitates 'sell to cover' transactions for tax purposes upon vesting.

Stakeholder Impact

• Minimal direct impact on shareholders as the transaction was a routine, non-discretionary sale to cover tax obligations, not a signal of management's view on the stock's future performance.

Key Dates

Recommendation

Keywords

NovoCure, NVCR, Form 4, insider transaction, share sale, director, stock transaction, RSU, restricted stock units, sell to cover, beneficial ownership